Sun Pharmaceutical Industries Ltd has entered into a binding agreement for acquiring Organon & Co for a cash deal worth US$ 11.75 billion, wherein US$ 14.00 per share will be offered to the stockholders of Organon. The move is intended to further strengthen the global profile of Sun Pharma and diversify its product portfolio especially in the fields of women’s health, biosimilar drugs, and branded generics. Organon is a leading multinational healthcare organization operating in more than 140 nations with a portfolio of more than 70 products. The merged firm is likely to become one of the top 25 pharmaceutical firms globally by leveraging synergies in terms of revenue scale, geographic presence, and innovation capacity.
Also Read: PacBio and Covaris Unlock FFPE Tumor Samples for Advanced HiFi Sequencing
Additionally, the acquisition facilitates the entry of Sun Pharma in the top 10 biosimilars segment globally. “This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform. We have deep respect for Organon’s mission and look forward to building on its legacy while driving sustainable long-term growth.” The transaction is expected to close in early 2027, subject to regulatory and shareholder approvals.
